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Snp‑Snp interactions of oncogenic 
long non‑coding RnAs HotAiR 
and Hottip on gastric cancer 
susceptibility
esmat Abdi1, Saeid Latifi‑Navid1*, Saber Zahri1, Vahid Kholghi‑oskooei2,3, 
Behdad Mostafaiy4, Abbas Yazdanbod5 & farhad pourfarzi5
Genetic variants within oncogenic long non‑coding RNAs HOTAIR and HOTTIP may affect their gene 
expression levels, thereby modifying genetic susceptibility to gastric cancer (GC). In a hospital‑based 
study in Ardabil—a very high‑risk area in North‑West Iran, 600 blood samples from 300 GC patients 
and 300 healthy controls were recruited for genotyping. Seven HOTAIR (i.e., rs17720428, rs7958904, 
rs1899663, and rs4759314) and HOTTIP (i.e., rs3807598, rs17501292, and rs1859168) ‘tag’ single 
nucleotide polymorphisms (SNPs) were genotyped by the Infinium HTS platform. The rs17720428, 
rs7958904, and rs1899663 tagSNPs significantly increased GC risk under dominant models by 1.5‑, 
1.57‑, and 1.5‑fold, respectively. The G‑C‑T‑A haplotype of HOTAIR tagSNPs increased the risk of 
GC by 1.31‑fold. No significant association was found between HOTTIP SNPs and the risk of GC. 
HOTAIR and HOTTIP variants were also not associated with any clinicopathologic characteristics. 
The SNP‑SNP interaction of HOTAIR rs17720428/rs7958904 with HOTTIP rs1859168 was associated 
with an increased risk of GC (rs17720428 TG‑rs1859168 CC, OR = 1.76; rs7958904 GC‑rs1859168 CC, 
OR = 1.85; rs7958904 CC‑rs1859168 CC, OR = 1.86). Interestingly, the SNP‑SNP interaction of HOTAIR 
rs1899663 with HOTTIP rs1859168 strongly increased the risk of GC (rs1899663 GT‑rs1859168 CC, 
OR = 4.3; rs1899663 TT‑rs1859168 CC, OR = 9.37; rs1899663 TT‑rs1859168 CA, OR = 6.59). We showed 
that the HOTAIR rs17720428, rs7958904, and rs1899663 tagSNPs and their interactions with the 
HOTTIP rs1859168 polymorphism significantly increased the risk of GC. Specifically, novel SNP‑SNP 
interactions between HOTAIR and HOTTIP tagSNPs have a larger impact than individual SNP effects 
on GC risk, thereby providing us with valuable information to reveal potential biological mechanisms 
for developing GC.
Gastric cancer (GC) is a prevalent disease of the digestive  system1–3. It is the fifth prevalent kind of cancer 
(5.7%) and the third cause of cancer-related mortality (8.2%)4. In spite of the incidence decline in some parts 
of the world, GC is a crucial challenge since most incidences are diagnosed at advanced stages, following poor 
 prognosis5,6. Thus, reliable biomarkers of GC must be identified for effective therapy, early diagnosis, and progno-
sis evaluation. Single nucleotide polymorphisms (SNPs) have profound to have influences on gene function and 
expression, and contribute to carcinogenesis. Studies of genome-wide association which scan the whole genome 
for prevalent genetic variants have shown over 450 SNPs related to susceptibility to different cancer  types7. Only 
7% of these loci are in protein-coding areas, but 93% are located in non-coding  areas8,9. Non-coding RNAs are 
the major regulators of some biological processes, including translation, transcription, epigenetic gene expres-
sion, splicing, cell cycle, embryogenesis, stem cell pluripotency and reprogramming, and the immune response 
 regulation10,11. Aberrant expression of long non-coding RNAs (lncRNAs) may bring about different  cancers12–14. 
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Various lncRNAs are associated with different cancer  types15–19. HOX transcript antisense RNA (HOTAIR)—a 
well-known oncogenic lncRNA—is highly expressed in GC tissues and has been recognized as a critical prog-
nostic biomarker for major cancers, including GC. HOTAIR inhibition not only reduces tumor invasiveness 
but also reverses EMT in GC cells by regulating N-cadherin, E-cadherin, vimentin, and a transcription factor 
snail. HOTAIR targets miR-126 to activate the multidrug resistance-associated protein 1/phosphatidylinositol 
3-kinase (PI3-K)/Akt and thus promotes cisplatin resistance in GC. Specifically, it directly inhibits miR126, 
promoting the expression of PI3-K regulatory subunit beta and vascular endothelial growth factor A. Therefore, 
HOTAIR-targeted therapies may potentially improve prognosis and survival of patients suffering from  GC15,20–22. 
The HOXA transcript at the distal tip (HOTTIP), transcribed from the 5′ tip of HOXA cluster, is a cancer-related 
 lncRNA23,24. Recruiting HOXA13–HOTAIR and HOXA13–HOTTIP to different sites in the promoter of bone 
morphogenetic protein 7 (BMP7) is critical for the oncogenic fate of the human gastric  cells24. HOTTIP was 
overexpressed significantly in cell lines of GC; HOTTIP down-regulation would hinder cell proliferation, degrade 
cell invasion and migration, and develop cell  apoptosis25. Ardabil Province is a very high-risk area in North-West 
Iran (ASRs, 51.8/100,000 and 24.9/100,000 for males and females, respectively), with one of the highest cardia 
GC (CGC) rates worldwide. Hence, in a case–control study from Ardabil, we genotyped seven HOTAIR (i.e., 
rs17720428, rs7958904, rs1899663, and rs4759314) and HOTTIP (i.e., rs3807598, rs17501292, and rs185916) 
tagSNPs to assess their associations with the risk of GC. In addition, to perform data mining regarding the SNP-
SNP interactions, all possible pair combinations between all of the HOTAIR and HOTTIP SNPs in relation to 
GC susceptibility were analyzed.
Results
General characteristics of the study subjects. Each of GC and control groups consisted of 300 subjects, 
of whom 74.7% were males. The average age (mean ± SD (min–max)) was 66.54 ± 10.43 (34–88) and 66.48 ± 9.71 
(38–91) years for cases and controls, respectively. Age and gender were not significantly different between the 
case and control groups (p = 0.37 and p = 1.00, respectively), which indicated that these groups were matched 
well with respect to these parameters. The genotype distributions of SNPs in cases and controls met the Hardy–
Weinberg equilibrium conditions (Table 1(. The prevalence rate of GC patients based on the anatomic site of 
the tumor origin was 52.5% with CGC, 35% with NCGC, and 12.5% with both CGC and NCGC. According to 
histopathologic features, the prevalence rate of the intestinal-, diffuse-, and indeterminate-type GC was 49.7%, 
19.7%, and 30.6%, respectively. Moreover, the 0.8, 5.2, 45.5 and 48.5% of patients were diagnosed at stages I, II, 
III, and IV, respectively. The clinical and demographic characteristics of the subjects are presented in Table 2.
The association between HOTAIR/HOTTIP tagSNPs and GC risk. The average call rate for the 
600 analyzed samples was 99.84%, showing high call rates and high reproducibility. Three SNPs of HOTAIR 
(i.e., rs17720428; rs7958904; rs1899663) were associated with an increased risk of GC. It was found that the 
rs17720428 polymorphism was associated with the risk of GC, assuming allelic, dominant, and log-additive 
models of inheritance. The findings revealed that the rs17720428 G allele was significantly associated with the 
increased risk of GC (G vs. T, OR = 1.27, 95% CI = 1.01–1.61; p = 0.04). In the dominant model, subjects carry-
ing the TG + GG genotype of rs17720428, as compared with those carrying the TT genotype, had a significantly 
higher risk of GC (OR = 1.5, 95% CI: 1.08–2.1; p = 0.01).
The rs7958904 SNP was associated with the risk of GC in allelic, co-dominant, dominant, and log-additive 
models of inheritance. The rs7958904 C allele was significantly associated with the increased risk of GC (C vs. 
G, OR = 1.31, 95% CI: 1.04–1.65; p = 0.02). Subjects carrying the CC or GC genotype of rs7958904, as compared 
with those carrying the GG genotype in the co-dominant model, showed an increased risk of GC (CC vs. GG, 
OR = 1.54, 95% CI: 1.07–2.22 and GC vs. GG, OR = 1.64, 95% CI: 1.03–2.62; p = 0.04). In the dominant model, 
subjects carrying the GC + CC genotype of rs7958904 showed an increased risk of GC in comparison with those 
carrying the GG genotype (OR = 1.57, 95% CI: 1.1–2.22; p = 0.01).
The rs1899663 SNP was associated with the risk of GC, assuming allelic, dominant and log-additive models 
of inheritance. The findings indicated that the rs1899663 T allele was significantly associated with the increased 
risk of GC (T vs. G, OR = 1.27, 95% CI: 1.01–1.61; p = 0.04). The GT + TT genotype of rs1899663, in com-
parison with GG genotype, had a significantly higher risk of GC in the dominant model (OR = 1.5, 95% CI: 
1.08–2.08; p = 0.02). No significant associations were observed between the rs4759314 SNP and GC susceptibility 
(Table 3). No evidence regarding the association between the HOTTIP tagSNPs (i.e., rs3807598, rs17501292, 
and rs1859168) and GC risk was found in any of the genetic models (p > 0.05; Table 4). The HOTAIR and HOT-
TIP variants were not associated with any clinicopathologic characteristics (Table 5). Moreover, the frequency 
of each HOTAIR/HOTTIP tagSNP did not show a significant difference between patients having stage I-II and 
stage III-IV disease (Table 6).
Table 1.  Exact test for Hardy–Weinberg equilibrium (p-value).
rs17720428 rs7958904 rs1899663 rs4759314 rs3807598 rs17501292 rs1859168
All subjects 0.37 0.87 0.73 1 0.12 0.06 0.43
Controls 0.61 0.4 0.61 1 0.56 0.06 0.36
Patients 0.23 0.56 0.23 1 0.11 0.07 0.51
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The association of haplotype in two lncRNA genes with GC risk. According to Table 7, the results 
of haplotype analysis showed that the G-C-T-A haplotype of HOTAIR rs17720428, rs7958904, rs1899663, and 
rs4759314, respectively, increased the risk of GC by 1.31-fold (95% CI: 1.03–1.67; p = 0.029). No haplotype of the 
three HOTTIP tagSNPs was associated with the risk of GC (p > 0.05).
SNP‑SNP interaction models for lncRNA polymorphisms. To perform data mining regarding 
the SNP-SNP interactions, all possible pair combinations between all of the HOTAIR and HOTTIP tagSNPs 
were analyzed. The interaction of HOTAIR rs17720428 TG with HOTTIP rs1859168 CC potentially increased 
the risk of GC (OR = 1.76, 95% CI: 1.22–2.54; p = 0.003). In addition, the interaction of HOTAIR rs7958904 
with HOTTIP rs1859168 potentially increased the risk of GC (rs7958904 GC-rs1859168 CC, OR = 1.85, 95% 
CI: 1.25–2.73, p = 0.002; rs7958904 CC-rs1859168 CC, OR = 1.86, 95% CI: 1.14–3.06, p = 0.01). Interestingly, 
the interaction of HOTAIR rs1899663 with HOTTIP rs1859168 strongly increased the risk of GC (rs1899663 
GT-rs1859168 CC, OR = 4.3, 95% CI: 2.75–6.7; rs1899663 TT-rs1859168 CC, OR = 9.37, 95% CI: 5.43–16.18; 
rs1899663 TT-rs1859168 CA, OR = 6.59, 95% CI: 2.12–20.51; all the p-values were < 0.001.) (Table 8).
the potential impact of each Snp on the establishment or destruction of the miRnA binding 
site. Bioinformatic analysis showed that the HOTAIR rs17720428/rs7958904 and HOTTIP rs17501292 tag-
SNPs cause miRNA target gain and loss. Moreover, the HOTTIP rs1859168 polymorphism could lead to miRNA 
target gain while the rs3807598 polymorphism could lead to miRNA target loss. For the HOTAIR rs1899663 and 
rs4759314 tagSNPs, no miRNA target gain or loss was recognized (Table 9).
Discussion
Evidences have demonstrated that the aberrant expression of lncRNAs may develop various  malignancies26,27. 
Moreover, polymorphisms in lncRNAs may influence their expression and bring about GC  susceptibility28,29. 
SNPs in lncRNAs may affect different biological processes through affecting biological pathways. Studies have 
confirmed the roles of lncRNAs as critical regulators of  tumorigenesis30. The current study explored whether 
the tagSNPs of HOTAIR (i.e., rs17720428, rs7958904, rs1899663, and rs4759314) and HOTTIP (i.e., rs3807598, 
rs17501292, and rs185916) affect GC development. The G allele and TG + GG genotype of rs17720428 in HOTAIR 
significantly increased the risk of GC (G vs. T, OR = 1.27; TG + GG vs. TT, OR = 1.5, respectively). We also showed 
Table 2.  Baseline characteristics of total 300 GC patients and 300 cancer-free controls.
Case
Age (mean ± SD (min–max)) – 66.54 ± 10.43 (34–88)
Gender
Male 74.7%
Female 25.3%
Tumor origin Cardia 52.5%
Cardia and non-cardia 12.5%
Non-cardia 35%
Pathology Intestinal-type GC 49.7%
Diffuse-type GC 19.7%
Other 30.6%
TNM Stage
I 0.8%
II 5.2%
III 45.5%
IV 48.5%
T
T1 9.4%
T2 18.1%
T3 24.2%
T4 48.3%
N
N0 1.1%
N1 2.6%
N2 35.3%
N3 60.9%
M
M0 51.9%
M1 48.1%
Control
Age (mean ± SD (min–max)) – 66.48 ± 9.71 (38–91)
Gender
Male 74.7
Female 25.3
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Table 3.  Genotype and allele frequencies of HOTAIR SNPs in cases and controls, and genotype- and 
allelotype-specific risks. OR, odds ratio; CI, confidence interval; SNPs, single nucleotide polymorphisms.
Locus Model Genotype Patients Controls Odds Ratio p-value
rs17720428
Allele
T 359 (59.8%) 393 (65.5%) 1 0.04
G 241 (40.21%) 207 (34.5%) 1.27 (1.01–1.61)
Codominant
TT 102 (34%) 131 (43.7%) 1 0.05
TG 155 (51.7%) 131 (43.7%) 1.52 (1.07–2.15)
GG 43 (14.3%) 38 (12.6%) 1.45 (0.87–2.41)
Dominant
TT 102 (34%) 131 (43.7%) 1 0.01
TG + GG 198 (66%) 169 (56.3%) 1. 5 (1.08–2.1)
Recessive
TT + TG 257 (85.7%) 262 (87.4%) 1 0.55
GG 43 (14.3%) 38 (12.6%) 1.15 (0.72–1.84)
Overdominant
TT + GG 145 (48.3%) 169 (56.3%) 1 0.05
TG 155 (51.7%) 131 (43.7%) 1.38 (1–1.9)
Log-Additive 1.28 (1.01–1.63) 0.04
rs7958904
Allele
G 315 (52.7%) 355 (59.4%) 1 0.02
C 283 (47.3%) 243 (40.6%) 1.31 (1.04–1.65)
Codominant
GG 80 (26.8%) 109 (36.5%) 1 0.04
GC 155 (51.8%) 137 (45.8%) 1.54 (1.07–2.22)
CC 64 (21.4%) 53 (17.7%) 1.64 (1.03–2.62)
Dominant
GG 80 (26.8%) 109 (36.5%) 1 0.01
GC + CC 219 (73.2%) 190 (63.5%) 1.57 (1.1–2.22)
Recessive
GG + GC 235 (78.6%) 246 (82.3%) 1 0.26
CC 64 (21.4%) 53 (17.7%) 1.26 (0.84–1.9)
Overdominant
GG + CC 144 (48.2%) 162 (54.2%) 1 0.14
GC 155 (51.8%) 137 (45.8%) 1.27 (0.92–1.75)
Log-Additive 1.31 (1.04–1.65) 0.02
rs1899663
Allele
G 358 (59.9%) 393 (65.5%) 1 0.04
T 240 (40.1%) 207 (34.5%) 1.27 (1.01–1.61)
Codominant
GG 102 (34.1%) 131 (43.7%) 1 0.06
GT 154 (51.5%) 131 (43.7%) 1.51 (1.06–2.13)
TT 43 (14.4%) 38 (12.7%) 1.45 (0.87–2.41)
Dominant
GG 102 (34.1%) 131 (43.7%) 1 0.02
GT + TT 197 (65.9%) 169 (56.3%) 1.5 (1.08–2.08)
Recessive
GG + GT 256 (85.6%) 262 (87.3%) 1 0.54
TT 43 (14.4%) 38 (12.7%) 1.16 (0.72–1.85)
Overdominant
GG + TT 145 (48.5%) 169 (56.3%) 1 0.05
GT 154 (51.5%) 131 (43.7%) 1.37 (0.99–1.89)
Log-Additive 1.28 (1.01–1.62) 0.04
rs4759314
Allele
A 586 (97.7%) 590 (98.3%) 1 0.41
G 14 (2.3%) 10 (1.7%) 1.41 (0.62–3.2)
Codominant
AA 286 (95.3%) 290 (96.7%) 1 0.4
AG 14 (4.7%) 10 (3.3%) 1.42 (0.62–3.25)
GG – – –
Dominant
– – – –
– – – –
Recessive
– – – –
– – – –
Overdominant
– – – –
– – – –
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that the T allele and GT + TT genotype of rs1899663 in HOTAIR were correlated with the higher GC risk (T vs. 
G, OR = 1.27; GT + TT vs. GG, OR = 1.5).
The C allele of rs7958904 in HOTAIR was correlated with the increased risk of GC (C vs. G, OR = 1.31). 
Patients carrying the GC or CC genotype of rs7958904 had considerably increased the risk of GC compared to 
those carrying the GG genotype (OR = 1.54 and GC vs. GG, OR = 1.64, respectively). In addition, subjects car-
rying the GC + CC genotype of rs7958904 possessed a meaningful increased risk of GC compared to individuals 
carrying the GG genotype (OR = 1.57). It has been shown that the HOTAIR rs7958904 CC genotype associates 
with the higher cervical cancer risk in comparison to the GG/GC genotypes (OR = 1.57). TCGA database revealed 
that the cervical cancer tissues with the rs7958904 CC genotype had increased the expression of HOTAIR com-
pared to those with GG genotype. Hence, HOTAIR rs7958904 may affect cervical cancer susceptibility by the 
modulation of CC cell  proliferation31. It is the possibility of additive roles of genetic and environmental factors 
with SNPs and understanding gene–gene/gene-environmental interactions are prerequisites for highly effective 
prevention.
Du et al. demonstrated that the HOTAIR SNP rs4759314 was significantly associated with the increased risk 
of GC (OR = 1.39). The HOXC11 and HOTAIR expression levels in the subjects with AG genotype were much 
higher than those with AA genotype. In the same vein, the promoter activity of G allele was more significant than 
Table 4.  Genotype and allele frequencies of HOTTIP SNPs in cases and controls, and genotype- and 
allelotype-specific risks. OR, odds ratio; CI, confidence interval; SNPs, single nucleotide polymorphisms.
Locus Model Genotype Patients Controls Odds Ratio p-value
rs3807598
Allele
C 315 (52.7%) 308 (51.5%) 1 0.68
G 283 (47.3%) 290 (48.5%) 0.95 (0.76–1.2)
Codominant
CC 90 (30.1%) 82 (27.4%) 1 0.71
CG 135 (45.2%) 144 (48.2%) 0.85 (0.58–1.24)
GG 74 (24.7%) 73 (24.4%) 0.92 (0.59–1.35)
Dominant
CC 90 (30.1%) 82 (27.4%) 1 0.47
CG + GG 209 (69.9%) 217 (72.6%) 0.89 (0.61–1.25)
Recessive
CC + CG 225 (75.3%) 226 (75.6%) 1 0.92
GG 74 (24.7%) 73 (24.4%) 1.02 (0.7–1.48)
Overdominant
CC + GG 164 (54.8%) 155 (51.8%) 1 0.46
CG 135 (45.2%) 144 (48.2%) 0.89 (0.64–1.22)
Log-Additive 0.96 (0.77–1.19) 0.69
rs17501292
Allele
T 492 (0.83) 514 (0.86) 1 0.1
G 104 (0.17) 84 (0.14) 1.29 (0.95–1.77)
Codominant
TT 208 (69.8%) 222 (74.3%) 1 0.29
TG 76 (25.5%) 70 (23.4%) 1.16 (0.8–1.69)
GG 14 (4.7%) 7 (2.3%) 2.13 (0.84–5.39)
Dominant
TT 208 (69.8%) 222 (74.3%) 1 0.23
TG + GG 90 (30.2%) 77 (25.7) 1.24 (0.87–1.78)
Recessive
TT + TG 284 (95.3%) 292 (97.7%) 1 0.12
GG 14 (4.7%) 7 (2.3%) 2.06 (0.82–5.17)
Overdominant
TT + GG 222 (74.5%) 229 (76.6%) 1 0.55
TG 76 (25.5%) 70 (23.4%) 1.12 (0.77–1.63)
Log-Additive 1.27 (0.94–1.72) 0.12
rs1859168
Allele
C 569 (95.2%) 561 (93.5%) 1 0.22
A 29 (4.8%) 39 (6.5%) 0.73 (0.45–1.2)
Codominant
CC 271 (90.7%) 263 (87.7%) 1 0.48
CA 27 (9%) 35 (11.7%) 0.75 (0.44–1.27)
AA 1 (0.3%) 2 (0.6%) 0.48 (0.04–5.38)
Dominant
CC 271 (90.7%) 263 (87.7%) 1 0.24
CA + AA 28 (9.3%) 37 (12.3%) 0.73 (0.48–1.23)
Recessive
CC + CA 298 (90.7%) 298 (99.4%) 1 0.56
AA 1 (0.3%) 2 (0.6%) 0.5 (0.04–5.54)
Overdominant
CC + AA 272 (91%) 265 (88.3%) 1 0.29
CA 27 (9%) 35 (11.7%) 0.75 (0.44–1.28)
Log-additive 0.74 (0.45–1.21) 0.22
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that of A  allele29. Finally, a meta-analysis study by Tao et al. showed that the HOTAIR rs4759314 polymorphism 
may play a role in GC  susceptibility32. In this case, all studies were in Chinese populations and therefore could 
not give an overview of its status in other populations. In contrast, we did not find any significant correlation 
between the HOTAIR rs4759314 SNPs and GC susceptibility. This may indicate the fact that some HOTAIR risk 
SNP(s) may be ancestry-specific; however, this is just a hypothesis and needs to be established, by studying this 
SNP in other types of cancer in Ardabil and in different (ethnic) population groups suffering from GC.
Only one haplotype in the HOTAIR (GCTA) gene was associated with the risk of GC (OR = 1.31). Studies 
have shown that different HOTAIR variants (e.g., rs920778, rs7958904, and rs874945) correlate with different 
cancers, including GC, colorectal cancer, breast cancer, and esophageal  cancer33. Knockdown of HOTAIR can 
prevent cell growth of GC, influence cell cycle distribution, and improve P21 and P53 protein  levels15.
HOTTIP knockdown in GC cells hindered cell proliferation, invasion, and migration. Additionally, HOTTIP 
down-regulation reduced the expression of homeobox protein Hox-A13 (HOXA13) in cell lines of GC. HOXA13 
affected GC cells’ HOTTIP-induced malignant phenotypes. Both HOXA13 and HOTTIP were up-regulated in 
GC tissues than adjacent noncancerous  tissues25. In the present study, none of the HOTTIP SNPs (i.e., rs3807598, 
rs17501292, and rs1859168) were associated with the risk of GC. In contrast, Hu et al. showed that HOTTIP 
rs1859168 A > C notably was associated with a decreased risk of pancreatic cancer (PC) (CC vs. AA: OR = 0.71). 
The C allele of HOTTIP rs1859168 could significantly reduce the relative luciferase activity in comparison to the 
A allele in three PC cell lines. Therefore, the functional rs1859168 A > C polymorphism could reduce the risk of 
PC by downregulating HOTTIP  expression34. This discrepancy between the two studies represents the hypothesis 
that some HOTTIP risk SNPs may be tissue-specific. However, further studies in different cancer cell lines are 
required to confirm such a hypothesis. In Hepatocellular carcinoma (HCC) patients, HOTTIP rs2071265 was 
related with an earlier recurrence. The HOTTIP suppression in cancer cell lines of liver decreased the rates of 
cell invasion and increased  chemosensitivity35. The interaction of HOTTIP rs17501292 with MALAT1 rs619586 
polymorphisms had a decreased impact on the risk of HCC (OR = 0.3)33.
In the present study, although none of the HOTTIP SNPs increased the risk of GC, the SNP-SNP interac-
tions of HOTAIR with HOTTIP were strongly associated with risk of GC. The SNP-SNP interaction of HOTAIR 
rs17720428 TG with HOTTIP rs1859168 CC increased the risk of GC (OR = 1.76). In addition, the SNP-SNP 
interaction of HOTAIR rs7958904 with HOTTIP rs1859168 increased the risk of GC (rs7958904 GC-rs1859168 
CC, OR = 1.85; rs7958904 CC-rs1859168 CC, OR = 1.86). Interestingly, the SNP-SNP interaction of HOTAIR 
Table 5.  Subgroup analysis of clinical characteristics for the association of SNPs with GC risk.
Gender Tumor origin Pathology
Male Female p-value Cardia
Cardia/Non-
cardia Non-cardia p-value
Intestinal-type 
GC Diffuse-type GC Others p-value
rs17720428 0.19 0.58 0.69
TT 80 (78.4%) 22 (21.6%) 56 (33.3%) 3 (66.7%) 43 (42.2%) 48 (47.1%) 20 (19.6%) 34 (33.3%)
TG 109 (70.3%) 46 (29.7%) 78 (50.6%) 3 (1.9%) 73 (47.4%) 81 (52.3%) 32 (20.6%) 42 (27.1%)
GG 35 (81.4%) 8 (18.6%) 27 (62.8%) 1 (2.3%) 15 (39.9%) 20 (46.5%) 7 (16.3%) 16 (37.2%)
rs7958904 0.31 0.54 0.85
GG 62 (77.5%) 18 (22.5%) 45 (56.3%) 2 (2.5%) 33 (41.3%) 37 (46.2%) 16 (20%) 27 (33.8%)
GC 110 (71%) 45 (29%) 80 (51.9%) 2 (1.3%) 72 (46.8%) 80 (51.6%) 32 (20.7%) 43 (27.7%)
CC 51 (79.7%) 13 (20.3%) 35 (54.7%) 3 (4.7%) 26 (40.6%) 32 (50%) 11 (17.2%) 21 (32.8%)
rs1899663 0.18 0.63 0.64
GG 80 (78.4%) 22 (21.6%) 55 (53.9%) 3 (2.9%) 44 (43.1%) 48 (47.1%) 20 (19.6%) 34 (33.3%)
GT 108 (70.1%) 46 (29.9%) 78 (51%) 3 (2%) 72 (47.1%) 81 (52.6%) 32 (20.8%) 42 (26.6%)
TT 35 (81.4%) 8 (18.6%) 27 (62.8%) 1 (2.3%) 15 (34.9%) 20 (46.5%) 7 (16.3%) 16 (37.2%)
rs4759314 0. 33 0.049 0.82
AA 212 (74.1%) 74 (25.9%) 155 (54.4%) 5 (1.8%) 125 (43.9%) 141 (49.3%) 57 (19.9%) 88 (30.8%)
AG 12 (85.7%) 2 (14.3%) 6 (42.9%) 2 (14.3%) 6 (42.9%) 8 (57.1%) 2 (14.3%) 4 (28.6%)
rs3807598 0.049 0.29 0.2
CC 61 (67.8%) 29 (32.2%) 43 (48.3%) 2 (2.3%) 44 (49.4%) 50 (55.6%) 19 (21.1%) 21 (23.3%)
CG 110 (81.5%) 25 (18.5%) 82 (60.7%) 3 (22.3%) 50 (37%) 58 (43%) 27 (20%) 50 (37%)
GG 52 (70.3%) 22 (29.7%) 36 (48.6%) 2 (2.7%) 36 (48.6%) 40 (54.1%) 13 (17.6%) 21 (28.4%)
rs17501292 0.08 0.96 0.44
TT 158 (76%) 50 (24%) 110 (52.9%) 5 (2.4%) 99 (44.7%) 97 (46.6%) 44 (21.2%) 67 (32.2%)
TG 59 (77.6%) 17 (22.4%) 42 (56%) 2 (2.7%) 31 (41.3%) 43 (56.6%) 14 (18.4%) 19 (25%)
GG 7 (50%) 7 (50%) 7 (50%) 0 (0%) 7 (50%) 8 (57.1%) 1 (7.1%) 5 (35.7%)
rs1859168 0.28 0.74 0.63
CC 206 (76%) 65 (24%) 145 (53.7%) 6 (2.2%) 119 (44.1%) 134 (49.4%) 53 (19.6%) 84 (31%)
CA 17 (63%) 10 (37%) 14 (51.9%) 1 (3.7%) 12 (44.4%) 14 (51.9%) 6 (22.2%) 7 (25.9%)
AA 1 (100%) 0 (0%) 1 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (100%)
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rs1899663 with HOTTIP rs1859168 strongly increased the risk of GC (rs1899663 GT-rs1859168 CC, OR = 4.3; 
rs1899663 TT-rs1859168 CC, OR = 9.37; rs1899663 TT-rs1859168 CA, OR = 6.59). To verify the findings and 
validate the results, further studies in diverse ethnicities and functional analysis are required.
In our research, the stratified analysis of genetic association of the HOTAIR and HOTTIP tagSNPs with 
clinicopathologic characteristics (such as tumor origin and intestinal-, diffuse-, or indeterminate-types of GC) 
revealed no significant association in all subgroups. An important problem in GC is that the most GC patients 
Table 6.  Relationship of clinical stage with HOTAIR/HOTTIP polymorphisms in GC patients.
Stage
I, II III, IV p-value
rs17720428 0.23
TT 7 (7.6%) 85 (92.4%)
TG 5 (3.7%) 130 (96.3%)
GG 4 (10.3%) 35 (89.7%)
rs7958904 0.08
GG 6 (8.5%) 65 (91.5%)
GC 4 (2.9%) 132 (97.1%)
CC 6 (10.3%) 52 (89.7%)
rs1899663 0.23
GG 7 (7.6%) 85 (92.4%)
GT 5 (3.7%) 130 (96.3%)
TT 4 (10.3%) 35 (89.7%)
rs4759314 0.85
AA 15 (6%) 237 (94%)
AG 1 (7.1%) 13 (92.9%)
rs3807598 0.98
CC 5 (6.2%) 75 (93.8%)
CG 7 (5.7%) 115 (94.3%)
GG 4 (6.3%) 59 (93.7%)
rs17501292 0.44
TT 9 (4.9%) 176 (95.1%)
TG 6 (9.2%) 59 (90.8%)
GG 1 (7.1%) 13 (92.9%)
rs1859168 0.41
CC 16 (6.7%) 224 (93.3%)
CA 0 (0%) 24 (100%)
AA 0 (0%) 1 (100%)
Table 7.  Association of the haplotype of HOTAIR/HOTTIP gene with GC risk were calculated using the 
SNPStats. https ://www.snpst ats.net/start .htm based on the expectation maximization algorithm.
HOTAIR rs17720428 rs7958904 rs1899663 rs4759314
Frequency in 
control group
Frequency in 
patients group OR (95%CI) p-value
T G G A 0.5948 0.5281 1 -
G C T A 0.3432 0.4 1.31 (1.03—1.67) 0.029
T C G A 0.0453 0.0469 1.16 (0.67—2.01) 0.61
T C G G 0.0149 0.0233 1.72 (0.73—4.08) 0.22
G C T G 0.0018 – – –
G C G A - 0.0017 – –
HOTTIP rs3807598 rs17501292 rs1859168 –
G T C – 0.4843 0.4696 1 -
C T C – 0.3181 0.3121 1.01 (0.78—1.31) 0.93
C G C – 0.1326 0.1676 1.28 (0.92—1.77) 0.14
C T A – 0.0571 0.0444 0.77 (0.45—1.32) 0.34
C G A – 0.0079 0.004 0.90 (0.16—4.94) 0.9
G G C – – 0.0024 – –
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are diagnosed at the advanced  stage36. In the present study, which was confined to Ardabil (a very high-risk area 
of GC in Northwestern Iran), the 0.8, 5.2, 45.5 and 48.5% of patients were diagnosed at stages I, II, III, and IV, 
respectively. The frequency of each HOTAIR or HOTTIP tagSNP did not show a significant difference between 
patients having stage I-II and stage III-IV disease. It might probably be explained by the fact that almost all the 
patients (94%) recruited in the study were at the advanced stage (III-IV), having poor prognosis.
The influence of lncRNAs on microRNA function and vice versa is emerging, affecting the gene expression 
programs. LncRNA tagSNPs can cause or destroy miRNA binding site(s) on the lncRNA. Some LncRNAs act as 
molecular decoys or sponges of microRNAs, with sequestrating microRNAs favoring the expression of suppressed 
target mRNAs. Other lncRNAs compete with miRNAs for interacting with shared target mRNAs, causing the 
derepression of gene expression. They can also be precursors to the production of miRNAs for silencing target 
mRNAs. In contrast, little is known about the influence of microRNAs on lncRNA function. They can target 
Table 8.  The two-way interaction of HOTAIR and HOTTIP polymorphism in the risk of GC.
SNP-SNP interaction SNP Genotype Patients Controls Odds Ratio p-value
rs17720428 and rs1859168 HOTAIR HOTTIP
TT CC 91 122 1
TT CA 10 9 1.49 (0.58–3.81) 0.4
TT AA 1 0
TG CC 143 109 1.76 (1.22–2.54) 0.003
TG CA 12 21 0.77 (0.39–1.64) 0.49
TG AA 0 1
GG CC 37 32 1.55 (0.9–2.67) 0.11
GG CA 5 5 1.34 (0.38–4.77) 0.65
GG AA 0 1
rs7958904 and rs1859168 HOTAIR HOTTIP
GG CC 70 103 1
GG CA 9 6 2.2 (0.75–6.47) 0.41
GG AA 1 0
GC CC 143 114 1.85 (1.25–2.73) 0.002
GC CA 12 22 0.8 (0.37–1.73) 0.57
GC AA 0 1
CC CC 57 45 1.86 (1.14–3.06) 0.01
CC CA 6 7 1.26 (0.4–3.91) 0.69
CC AA 0 1
rs1899663 and rs1859168 HOTAIR HOTTIP
GG CC 37 122 1
GG CA 5 9 1.83 (0.59–5.8) 0.3
GG AA
GT CC 142 109 4.3 (2.75–6.7)  < 0.001
GT CA 12 21 1.88 (0.85–4.19) 0.12
GT AA 0 1
TT CC 91 32 9.37 (5.43–16.18)  < 0.001
TT CA 10 5 6.59 (2.12–20.51)  < 0.001
TT AA 1 1 3.3 (0.2–54.01) 0.38
Table 9.  The potential impact of each SNP on the establishment or destruction of the miRNA binding site.
SNP causes miRNA target gain SNP causes miRNA target loss
rs17720428 hsa-miR-6513-5p, hsa-miR-450b-3p, hsa-miR-5089-5p, hsa-miR-769-3p, hsa-miR-5004-3p,
rs7958904 hsa-miR-6721-5p, hsa-miR-1203 hsa-miR-4750-3p, hsa-miR-615-3p, hsa-miR-6742-5p
rs1899663 – –
rs4759314 – –
rs3807598 – hsa-miR-3115
rs17501292 hsa-miR-8080 hsa-miR-1252-5p, hsa-miR-651-3p, hsa-miR-5681a
rs1859168 hsa-miR-5699-5p, hsa-miR-874-5p, hsa-miR-506-5p, hsa-miR-216a-5p –
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lncRNAs for  degradation37,38. Here, using bioinformatic analysis, we showed that the HOTAIR rs17720428/
rs7958904 and HOTTIP rs17501292/rs1859168/rs3807598 tagSNPs could lead to miRNA target gain and/or loss. 
However, for the HOTAIR rs1899663 and rs4759314 tagSNPs, no miRNA target gain or loss was recognized. 
Among the miRNAs listed in Table 9, for a small number, the functional role has been recently determined to a 
somewhat large extent in cancer, although not necessarily in GC, including the miR-615-3p, miR-874-5p, miR-
506-5p, miR-769-3p, miR-1252-5p, and especially miR-216a-5p. For example, miR-615-3p can promote the 
epithelial mesenchymal transition (EMT) and metastasis of breast cancer by targeting protein interacting with 
C kinase 1 (PICK1)/TGFBRI  axis39. MicroRNA-874-mediated inhibition of the major G1/S phase cyclin, cyclin 
E1 (CCNE1) does not occur in osteosarcomas. It also inhibits tumor metastasis in hepatocellular carcinoma by 
targeting the δ opioid receptor (DOR)/epidermal growth factor receptor (EGFR)/extracellular signal-regulated 
kinase (ERK)  pathway40,41. MiR-506 inhibits the proliferation and invasion of i) colorectal cancer by targeting 
ubiquitin-like with plant homeodomain and RING finger domains 1 (UHRF1) via the KISS1/PI3K/NF-kB sign-
aling axis and ii) nasopharyngeal carcinoma by targeting Forkhead box Q1 (FOXQ1), and is also epigenetically 
silenced in pancreatic  cancer42–44. During Reoxygenation microRNA-769-3p down-regulates N-myc downstream-
regulated gene 1 (NDRG1) and enhances  Apoptosis45. By targeting miR-1252-5p, the lncRNA AL161431.1 can 
facilitate cellular proliferation and migration via MAPK signaling in endometrial  carcinoma46. The function of 
miR-216a-5p has also been studied in depth in various cancers, playing a role of tumor suppressor. It inhibits 
the cell proliferation and metastasis by targeting Janus kinase 2 (JAK2)/signal transducer and activator of tran-
scription 3 (STAT3)-mediated EMT process in GC and by targeting p21-activated protein kinase 2 (PAK2) in 
breast cancer. It also inhibits the cell proliferation and induces apoptosis by targeting tectonic family member 
1 (TCTN1) in esophageal squamous cell carcinoma. Moreover, the low expression of miR-216a results in the 
upregulation of tetraspanin 1 (TSPAN1) that contributes to pancreatic cancer progression via transcriptional 
regulation of integrin alpha 2 (ITGA2)47–50.
Except for miR-615-3p and miR-1252-5p, which have lost their potential binding sites to HOTAIR (due to 
rs7958904 polymorphism) and HOTTIP (due to rs17501292 polymorphism), respectively and are thought to be 
oncogenic, the other four molecules including miR-874-5p, miR-506-5p, miR-769-3p, and miR-216a-5p play the 
role of tumor suppressors. MiR-615-3p and miR-1252-5p molecules may retain their oncogenic effect due to the 
loss of their binding site to HOTAIR and HOTTIP, respectively; however, the possible mechanism(s) is unknown 
and requires functional studies. MiR-769-3p has a potential binding site to HOTAIR due to the rs17720428 
polymorphism associated with GC in the present study. Interestingly, all the three molecules miR-874-5p, miR-
506-5p, and miR-216a-5p have a possible binding site to HOTTIP due to rs1859168 polymorphism. In the present 
study, the SNP-SNP interaction of HOTAIR rs1899663 with HOTTIP rs1859168 was strongly associated with 
GC, which may be due to the destruction of these molecules that are thought to function as tumor suppressors. 
However, functional studies need to be done to determine if these bindings actually occur and what the role of 
binding of these molecules to HOTTIP is in the progression to GC. These studies should be performed in the 
presence of HOTTIP rs1859168 tagSNPs by controlling the presence of HOTAIR rs1899663 polymorphism.
Taking altogether, we showed that HOTAIR rs17720428, rs7958904, and rs1899663 tagSNPs and their inter-
actions with the HOTTIP rs1859168 polymorphism were significantly associated with GC risk. Specifically, 
novel SNP-SNP interactions between HOTAIR and HOTTIP tagSNPs have a larger impact than individual SNP 
effects on GC risk, thereby providing us with valuable information to reveal potential biological mechanisms 
for developing GC.
Materials and methods
Study subjects. A hospital-based case–control study, from October 2017 to February 2019, was conducted. 
A total of 300 cases were selected from patients undergoing endoscopic examination in the Imam Khomeini 
Hospital in the Ardabil. One control was sought for each case, frequency matched to the case group by 5-year age 
groups and gender. The controls were randomly selected from subjects who received routine physical examina-
tions in the same hospital and had no self-reported history of cancer at any site. According to histopathologic 
and endoscopic results, gastroduodenal disease was diagnosed. GC diagnoses were categorized by anatomic sub-
sites based on the International Classification of Diseases,  10th Revision (ICD-10) as cardia (ICD-10 code C16.0) 
and non-cardia (ICD-10 codes C16.1–C16.9, involving unspecified and overlapping subsites)51. According to the 
classification of Lauren, histologic subtypes were assessed as diffuse-type, intestinal-type, and other/unspecified 
 histologies52. Finally, the AJCC 8th TNM staging system for GC was considered, showing an improved efficiency 
in GC  prognosis53. The study was conducted on the basis of ethical principles of human research expressed in 
the 1975 Declaration of Helsinki. All participants signed an informed consent form. This study was approved 
by the Ethics Committee of the National Institute for Medical Research Development (NIMAD)/ IR.NIMAD.
REC.1396.097.
SNP selection and genotyping. The data of genetic polymorphism from the entire sequence of lncRNAs 
was achieved from the dbSNP database (https ://www.ncbi.nlm.nih.gov/proje cts/SNP/). The lncRNA HOTTIP 
gene sequences were downloaded by the 1000 Genomes Browser (https ://www.ncbi.nlm.nih.gov/varia tion/tools 
/1000g enome s/) after enlarging 2 kb of upstream and downstream flanking sequences of the gene. The selection 
criteria were: (i) linkage disequilibrium (LD) r2 lower than 0.8, (ii) minor allele frequency (MAF) higher than 
0.05, and (iii) the p-value of Hardy–Weinberg equilibrium (HWE) higher than 0.05. Seven eligible tagSNPs were 
chosen involving four SNPs for HOTAIR (i.e., rs17720428, rs7958904, rs1899663, and rs4759314) and three 
SNPs for HOTTIP (i.e., rs3807598, rs17501292, and rs17501292) eventually included in the final analysis. From 
each participant, venous blood samples were taken into an ethylenediaminetetraacetic acid (EDTA)-containing 
tube and were stored at -80 °C. Using QIAamp DNA blood mini kit (QIAGEN, Germany), genomic DNA was 
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extracted from 200 µL peripheral blood samples as previously  described54. All samples were genotyped by the 
Infinium HTS platform according to the standard protocol (https ://www.illum ina.com/Docum ents/produ cts/
workfl ows/workfl ow_infin ium_ii.pdf) with a customized Illumina Infinium GSA BeadChip—a robust, high-
quality assay. This SNP microarray uses known nucleotide sequences as probes to hybridize with the tested 
DNA sequences, allowing a qualitative and quantitative SNP analysis. Data quality control was performed using 
Genome Studio. The call rate cut-off was 98% as it an off-the-shelf array.
Statistical and bioinformatic analysis. Genotyping results of SNPs were evaluated for significant 
departure from Hardy–Weinberg equilibrium. Using Pearson chi-square test or Fisher’s exact probability (for 
categorical variables), the variations in frequency distribution of genotypes and demographic characteristics 
were assessed. The association strength was calculated applying odds ratios (ORs) and 95% confidence inter-
vals (CIs). All genetic models were evaluated, including dominant, recessive, co-dominant, over dominant, and 
log additive models of inheritance for seven SNPs. Each model provides different assumptions regarding the 
genetic effect. Using the SNPStats (https ://www.snpst ats.net/start .htm), haplotype frequencies were obtained 
for HOTAIR and HOTTIP according to the expectation maximization algorithm. The pairwise interactions of 
lncRNA SNP-SNP were calculated. Statistical analyses were done by SPSS version 19.0 (IBM, Chicago, USA). 
The correlations between every genetic variant and clinical features of GC were investigated. The statistical tests 
were two-sided; p < 0.05 was assumed statistically significant. The potential impact of each SNP on the establish-
ment or destruction of the miRNA binding site was analyzed using the lncRNASNP2  database55.
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable 
request.
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